T. Rowe Price

Investment Thesis

T. Rowe Price's growth equity strategy focuses on identifying high-quality companies with strong fundamentals and long-term growth potential. In healthcare and life sciences, they invest in companies with differentiated technologies, large market opportunities, and clear paths to profitability. They often serve as anchor investors in late-stage private rounds and IPOs.

Team

Partners / Portfolio Managers (Health Focus)

• Henry Ellenbogen - Former Chief Investment Officer (now at Durable Capital)
• Alan Tu - Portfolio Manager, Healthcare
• Taymour Tamaddon - Portfolio Manager, Healthcare

Other Key Team Members

• Healthcare Research Team - Sector analysts covering biotechnology, pharmaceuticals, healthcare services
• Private Markets Team - Growth equity specialists

Focus Areas

• Biotechnology
• Pharmaceuticals
• Healthcare Technology
• Medical Devices
• Healthcare Services
• Digital Health
• Precision Medicine

Notable Portfolio Companies (Healthcare/Biotech)

• Tempus AI - AI-enabled precision medicine (Series G investor)
• Moderna - mRNA therapeutics (pre-IPO investor)
• 10x Genomics - Single-cell genomics
• Guardant Health - Liquid biopsy
• Grail - Cancer detection

Notable Investments

• Major institutional investor in healthcare IPOs
• Anchor investor in numerous biotech public offerings
• Cross-over investor bridging private to public markets

Recognition

• One of the world's largest asset managers
• Publicly traded (NASDAQ: TROW)
• Long history of healthcare sector expertise

Sources

• T. Rowe Price website: https://www.troweprice.com
• SEC filings and 13F reports
• Bloomberg, Reuters coverage